COMP <GO>
INSM vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY
Insmed Incorporated (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: INSM 5
— JNJ 8
■ METRIC PARITY
LAST: $112.58 (+0.89%) • MKT CAP: $24.37B
dividend-safety
0.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSM VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSM | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.70% | 67.90% | +11.80 | INSM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.97% | 2.97% | -6.94 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 66.70% | 6.00% | +60.70 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.25 | 5.59 | -0.34 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.20% | -0.20 | INSM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.7 | 60.4 | +2.38 | INSM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.03 | 1.08 | -0.05 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 23.0x | -2.00 | INSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.37B | $662.49B | -$638.12B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSM REV | JNJ REV | INSM GROSS % | JNJ GROSS % | INSM FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $606.4M | $94.19B | 79.7% | 67.9% | -$967.6M | $19.70B |
| FY 2024 | $363.7M | $88.82B | 76.4% | 69.1% | -$705.8M | $19.84B |
| FY 2023 | $305.2M | $85.16B | 44.0% | 44.0% | -$550.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSM // BETA 1.03
JNJ // BETA 1.08